Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Phase 2 obesity data published in The New England Journal of Medicine showed large average weight reductions, which helped establish retatrutide as one of the most closely watched next-generation obesity drugs in development
Overall the study concluded that AOD9604 was shown to be beneficial in obese mice both with and without the beta(3)-adrenergic receptors present
Gradinaru D, Borsa C, Ionescu C, Margina D, Prada GI, Jansen E
Researchers led by Venky Soundararajan analyzed de-identified electronic health records from academic medical centers in the United States, focusing on patients treated with tirzepatide and semaglutide
US$ 22.53
US$ 21.89
US$ 24.19
